WO2002005870A3 - Kits et compositions pour la realisation d'injections intracraniennes - Google Patents

Kits et compositions pour la realisation d'injections intracraniennes Download PDF

Info

Publication number
WO2002005870A3
WO2002005870A3 PCT/US2001/022539 US0122539W WO0205870A3 WO 2002005870 A3 WO2002005870 A3 WO 2002005870A3 US 0122539 W US0122539 W US 0122539W WO 0205870 A3 WO0205870 A3 WO 0205870A3
Authority
WO
WIPO (PCT)
Prior art keywords
components
compositions
kit
nutrient
constituent
Prior art date
Application number
PCT/US2001/022539
Other languages
English (en)
Other versions
WO2002005870A2 (fr
Inventor
David P Hesson
Glenn David Frazer
Timothy J Pelura
Original Assignee
Neuron Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuron Therapeutics Inc filed Critical Neuron Therapeutics Inc
Priority to EP01954737A priority Critical patent/EP1301226A4/fr
Priority to AU2001276963A priority patent/AU2001276963A1/en
Publication of WO2002005870A2 publication Critical patent/WO2002005870A2/fr
Publication of WO2002005870A3 publication Critical patent/WO2002005870A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological
    • A61M2202/0476—Oxygenated solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0693—Brain, cerebrum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Cette invention se rapporte notamment à un kit fournissant des quantités prémesurées de composants, pour former une émulsion d'éléments nutritifs au fluorocarbone capable de transporter de l'oxygène dans des tissus vivants, ce kit comprenant: des solutions de constituants, des émulsions de constituants ou des compositions particulaires, qui sont les compositions de constituants contenant des quantités prémesurées de composants destinés à produire l'émulsion d'éléments nutritifs au fluorocarbone, ces compositions de constituants comprenant: un composé polyfluoré transporteur d'oxygène; un agent émulsifiant physiologiquement acceptable propre à émulsifier le polymère; une quantité d'hydrates de carbone propre à fournir des éléments nutritifs; des quantités d'acides aminés ou de précurseurs d'acide aminé propres à fournir des éléments nutritifs; un agent oncotique en quantité suffisante pour produire, associé aux autres composants de la solution, une pression oncotique physiologiquement acceptable; et des sels et des agents de tamponnage en suffisance pour produire une pression osmotique physiologique et des concentrations physiologiquement appropriées d'ions potassium et sodium; ces compositions de constituants étant choisies pour assurer une stabilité suffisante des composants, en vue de permettre la commercialisation du kit.
PCT/US2001/022539 2000-07-19 2001-07-18 Kits et compositions pour la realisation d'injections intracraniennes WO2002005870A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01954737A EP1301226A4 (fr) 2000-07-19 2001-07-18 Kits et compositions pour la realisation d'injections intracraniennes
AU2001276963A AU2001276963A1 (en) 2000-07-19 2001-07-18 Kits and compositions supporting intracranial perfusions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61941400A 2000-07-19 2000-07-19
US09/619,414 2000-07-19

Publications (2)

Publication Number Publication Date
WO2002005870A2 WO2002005870A2 (fr) 2002-01-24
WO2002005870A3 true WO2002005870A3 (fr) 2002-08-15

Family

ID=24481828

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/022539 WO2002005870A2 (fr) 2000-07-19 2001-07-18 Kits et compositions pour la realisation d'injections intracraniennes

Country Status (3)

Country Link
EP (1) EP1301226A4 (fr)
AU (1) AU2001276963A1 (fr)
WO (1) WO2002005870A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1370138A4 (fr) * 2001-03-02 2004-08-18 Neuron Therapeutics Inc Therapie genique pour tissus neurologiques
EP2124539A2 (fr) 2007-02-17 2009-12-02 President and Fellows of Harvard College Compositions et procede de conservation de tissu
CN102088968A (zh) 2008-02-15 2011-06-08 哈佛学院董事会 血液替代溶液

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686085A (en) * 1980-04-14 1987-08-11 Thomas Jefferson University Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders
US6316403B1 (en) * 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981691A (en) * 1980-04-14 1991-01-01 Thomas Jefferson University Oxygenated fluorocarbon nutrient solution
SE8505048L (sv) * 1985-10-25 1987-04-26 Nutritional Int Res Inst Nutritionsemulsion med syretransporterande egenskaper
WO1988005261A1 (fr) * 1987-01-16 1988-07-28 Tops Systems, Inc. Systeme de perfusion totale pour organes
US6500809B1 (en) * 1999-11-12 2002-12-31 Neuron Therapeutics, Inc. Hyperoncotic artificial cerebrospinal fluid and method of treating neural tissue edema therewith

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686085A (en) * 1980-04-14 1987-08-11 Thomas Jefferson University Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders
US6316403B1 (en) * 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1301226A4 *

Also Published As

Publication number Publication date
WO2002005870A2 (fr) 2002-01-24
EP1301226A4 (fr) 2004-07-14
AU2001276963A1 (en) 2002-01-30
EP1301226A2 (fr) 2003-04-16

Similar Documents

Publication Publication Date Title
CN100381048C (zh) 评价和保存溶液
ES2052495T5 (es) Terapia de fluidos con aniones l-lactato y/o piruvato.
CA1270199A (fr) Conservation de tissus vivants
DE59812766D1 (de) Lösung für die Peritonealdialyse
AU2696001A (en) Physiological medium for perfusing, preserving and storing isolated cell, tissueand organ samples
WO2006073164A1 (fr) Preparation pour dialyse
BRPI0410116A (pt) tablete de cuidado oral
WO2010055963A1 (fr) Procédé de fabrication d'une composition de dialysat exempt d'acétate
CA2229746A1 (fr) Utilisation de l-citrulline en medecine orthomoleculaire a des fins de vasoprotection, de relaxation du tonus des muscles lisses et de protection cellulaire
AU2001293851A1 (en) Stabilized hydrogen peroxide solutions
FR2762849A1 (fr) Solution aqueuse d'entretien des lentilles de contact
DE50104197D1 (de) Stabile Infusionslösung von Diclofenac-Salzen, deren Herstellung und Verwendung
ATE459336T1 (de) Formulierung zur dermalen anwendung
EP0414373A2 (fr) Solution stable d'hyaluronate dans un milieu salin équilibré
WO2002005870A3 (fr) Kits et compositions pour la realisation d'injections intracraniennes
BR9914644A (pt) Composições tamponadas para diálise
WO1996008244A1 (fr) Gouttes pour soigner la cornee
Förster et al. Reduced nitric oxide release causes nitrate tolerance in the intact coronary circulation
AR037964A1 (es) Formulaciones agricolas de baja viscosidad y alta concentracion
Jessen Taurine and β-alanine transport in an established human kidney cell line derived from the proximal tubule
EP0562188B1 (fr) Composition pour les tissus destinée à soutenir la viabilité et les fonctions biologiques pendant la chirurgie et la stockage
EP0208709A1 (fr) Concentre bacteriostatique d'hemodialyse
Akan et al. Comparison of three different irrigation fluids used in transurethral prostatectomy based on plasma volume expansion and metabolic effects
Breborowicz et al. Intracellular glutathione in human peritoneal mesothelial cells exposed in vitro to dialysis fluid
ATE331507T1 (de) Stabile pharmazeutische zusammensetzung mit safingol und verfahren zu dessen verwendung

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2001954737

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001954737

Country of ref document: EP

ENP Entry into the national phase

Country of ref document: RU

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Country of ref document: RU

Kind code of ref document: A

Format of ref document f/p: F

WWW Wipo information: withdrawn in national office

Ref document number: 2001954737

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP